|
1
|
Rossi E, Vita A, Baccetti S, Di Stefano M,
Voller F and Zanobini A: Complementary and alternative medicine for
cancer patients: Results of the EPAAC survey on integrative
oncology centres in Europe. Support Care Cancer. 23:1795–1806.
2015. View Article : Google Scholar
|
|
2
|
Ventola CL: Current issues regarding
complementary and alternative medicine (CAM) in the United States:
Part 1: The widespread use of CAM and the need for better-informed
health care professionals to provide patient counseling. P T.
35:461–468. 2010.PubMed/NCBI
|
|
3
|
Tuorkey MJ: Curcumin a potent cancer
preventive agent: Mechanisms of cancer cell killing. Interv Med
Appl Sci. 6:139–146. 2014. View Article : Google Scholar
|
|
4
|
Duvoix A, Blasius R, Delhalle S,
Schnekenburger M, Morceau F, Henry E, Dicato M and Diederich M:
Chemopreventive and therapeutic effects of curcumin. Cancer Lett.
223:181–190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kamat AM, Sethi G and Aggarwal BB:
Curcumin potentiates the apoptotic effects of chemotherapeutic
agents and cytokines through down-regulation of nuclear
factor-kappaB and nuclear factor-kappaB-regulated gene products in
IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer
cells. Mol Cancer Ther. 6:1022–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kunnumakkara AB, Guha S, Krishnan S,
Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates
antitumor activity of gemcitabine in an orthotopic model of
pancreatic cancer through suppression of proliferation,
angiogenesis, and inhibition of nuclear factor-kappaB-regulated
gene products. Cancer Res. 67:3853–3861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian F, Fan T, Zhang Y, Jiang Y and Zhang
X: Curcumin potentiates the antitumor effects of 5-FU in treatment
of esophageal squamous carcinoma cells through downregulating the
activation of NF-κB signaling pathway in vitro and in vivo. Acta
Biochim Biophys Sin (Shanghai). 44:847–855. 2012. View Article : Google Scholar
|
|
8
|
Li L, Braiteh FS and Kurzrock R:
Liposome-encapsulated curcumin: In vitro and in vivo effects on
proliferation, apoptosis, signaling, and angiogenesis. Cancer.
104:1322–1331. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sasaki H, Sunagawa Y, Takahashi K,
Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H,
Fujita M, et al: Innovative preparation of curcumin for improved
oral bioavailability. Biol Pharm Bull. 34:660–665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bisht S, Feldmann G, Soni S, Ravi R,
Karikar C and Maitra A and Maitra A: Polymeric
nanoparticle-encapsulated curcumin ('nanocurcumin'): A novel
strategy for human cancer therapy. J Nanobiotechnology. 5:32007.
View Article : Google Scholar
|
|
11
|
Anand P, Nair HB, Sung B, Kunnumakkara AB,
Yadav VR, Tekmal RR and Aggarwal BB: Design of curcumin-loaded PLGA
nanoparticles formulation with enhanced cellular uptake, and
increased bioactivity in vitro and superior bioavailability in
vivo. Biochem Pharmacol. 79:330–338. 2010. View Article : Google Scholar
|
|
12
|
Ho JN, Byun SS, Lee S, Oh JJ, Hong SK, Lee
SE and Yeon JS: Synergistic antitumor effect of triptolide and
cisplatin in cisplatin resistant human bladder cancer cells. J
Urol. 193:1016–1022. 2015. View Article : Google Scholar
|
|
13
|
Philippou Y, Hadjipavlou M, Khan S and
Rane A: Complementary and alternative medicine (CAM) in prostate
and bladder cancer. BJU Int. 112:1073–1079. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Klempner SJ and Bubley G: Complementary
and alternative medicines in prostate cancer: From bench to
bedside? Oncologist. 17:830–837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kamat AM, Tharakan ST, Sung B and Aggarwal
BB: Curcumin potentiates the antitumor effects of Bacillus
Calmette-Guerin against bladder cancer through the downregulation
of NF-kappaB and upregulation of TRAIL receptors. Cancer Res.
69:8958–8966. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tian B, Wang Z, Zhao Y, Wang D, Li Y, Ma
L, Li X, Li J, Xiao N, Tian J, et al: Effects of curcumin on
bladder cancer cells and development of urothelial tumors in a rat
bladder carcinogenesis model. Cancer Lett. 264:299–308. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lao CD, Ruffin MT IV, Normolle D, Heath
DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL and Brenner
DE: Dose escalation of a curcuminoid formulation. BMC Complement
Altern Med. 6:102006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanai M, Imaizumi A, Otsuka Y, Sasaki H,
Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H and Chiba T:
Dose-escalation and pharmacokinetic study of nanoparticle curcumin,
a potential anticancer agent with improved bioavailability, in
healthy human volunteers. Cancer Chemother Pharmacol. 69:65–70.
2012. View Article : Google Scholar
|
|
19
|
Kanai M, Otsuka Y, Otsuka K, Sato M,
Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S,
et al: A phase I study investigating the safety and
pharmacokinetics of highly bioavailable curcumin (Theracurmin) in
cancer patients. Cancer Chemother Pharmacol. 71:1521–1530. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morimoto T, Sunagawa Y, Katanasaka Y,
Hirano S, Namiki M, Watanabe Y, Suzuki H, Doi O, Suzuki K, Yamauchi
M, et al: Drinkable preparation of Theracurmin exhibits high
absorption efficiency - a single-dose, double-blind, 4-way
crossover study. Biol Pharm Bull. 36:1708–1714. 2013. View Article : Google Scholar
|
|
21
|
Milano F, Mari L, van de Luijtgaarden W,
Parikh K, Calpe S and Krishnadath KK: Nano-curcumin inhibits
proliferation of esophageal adenocarcinoma cells and enhances the T
cell mediated immune response. Front Oncol. 3:1372013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park C, Kim GY, Kim GD, Choi BT, Park YM
and Choi YH: Induction of G2/M arrest and inhibition of
cyclooxygenase-2 activity by curcumin in human bladder cancer T24
cells. Oncol Rep. 15:1225–1231. 2006.PubMed/NCBI
|
|
23
|
Aggarwal BB, Banerjee S, Bharadwaj U, Sung
B, Shishodia S and Sethi G: Curcumin induces the degradation of
cyclin E expression through ubiquitin-dependent pathway and
up-regulates cyclin-dependent kinase inhibitors p21 and p27 in
multiple human tumor cell lines. Biochem Pharmacol. 73:1024–1032.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nowsheen S and Yang ES: The intersection
between DNA damage response and cell death pathways. Exp Oncol.
34:243–254. 2012.PubMed/NCBI
|
|
25
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kunnumakkara AB, Anand P and Aggarwal BB:
Curcumin inhibits proliferation, invasion, angiogenesis and
metastasis of different cancers through interaction with multiple
cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He M, Li Y, Zhang L, Li L, Shen Y, Lin L,
Zheng W, Chen L, Bian X, Ng HK, et al: Curcumin suppresses cell
proliferation through inhibition of the Wnt/β-catenin signaling
pathway in medulloblastoma. Oncol Rep. 32:173–180. 2014.PubMed/NCBI
|
|
29
|
Lu Y, Wei C and Xi Z: Curcumin suppresses
proliferation and invasion in non-small cell lung cancer by
modulation of MTA1-mediated Wnt/β-catenin pathway. In Vitro Cell
Dev Biol Anim. 50:840–850. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park CH, Hahm ER, Park S, Kim HK and Yang
CH: The inhibitory mechanism of curcumin and its derivative against
beta-catenin/Tcf signaling. FEBS Lett. 579:2965–2971. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alexandrow MG, Song LJ, Altiok S, Gray J,
Haura EB and Kumar NB: Curcumin: A novel Stat3 pathway inhibitor
for chemoprevention of lung cancer. Eur J Cancer Prev. 21:407–412.
2012. View Article : Google Scholar :
|
|
32
|
Xu X, Qin J and Liu W: Curcumin inhibits
the invasion of thyroid cancer cells via down-regulation of
PI3K/Akt signaling pathway. Gene. 546:226–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou H, Beevers CS and Huang S: The
targets of curcumin. Curr Drug Targets. 12:332–347. 2011.
View Article : Google Scholar :
|
